AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Revenio Group Oyj

Share Issue/Capital Change Dec 29, 2020

3236_dva_2020-12-29_afd1cba7-8179-453e-8405-8e7e9d6e684b.pdf

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, December 29, 2020 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Total of 2,013 new share subscriptions based on the company's 2015C stock options approved by the Board of Directors of Revenio Group Corporation on December 17, 2020, have been entered into the trade register today. The share subscription price under 2015C option rights was 12.48 EUR per share. The subscription period for 2015C options is May 31, 2019 – May 31, 2021.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,658,952. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on December 30, 2020.

Revenio Group Corporation Board of Directors

For further information, please contact:

Jouni Toijala, CEO, tel. +358 50 484 0085 [email protected] www.revenio.fi

The Revenio Group in brief

Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

In 2019, the Group's net sales totaled EUR 49.5 million, with its operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Increased number of shares entered into trade register

Talk to a Data Expert

Have a question? We'll get back to you promptly.